vs

Side-by-side financial comparison of FRANKLIN WIRELESS CORP (FKWL) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.9M, roughly 1.0× FRANKLIN WIRELESS CORP). FRANKLIN WIRELESS CORP runs the higher net margin — 4.5% vs -1398.3%, a 1402.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -33.1%). FRANKLIN WIRELESS CORP produced more free cash flow last quarter ($-4.1M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 39.0%).

Viaero Wireless is a regional wireless telecommunications company that provides direct coverage in Nebraska, eastern Colorado, western Kansas, and southeastern Wyoming. Based in Fort Morgan, Colorado, Viaero is often the primary cell tower owner in portions of its coverage area. Through roaming coverage partner relationships, Viaero customers can place and receive calls locally and across the country, internationally, and on cruise ships.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FKWL vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.0× larger
RNA
$12.5M
$11.9M
FKWL
Growing faster (revenue YoY)
RNA
RNA
+467.1% gap
RNA
434.0%
-33.1%
FKWL
Higher net margin
FKWL
FKWL
1402.8% more per $
FKWL
4.5%
-1398.3%
RNA
More free cash flow
FKWL
FKWL
$152.8M more FCF
FKWL
$-4.1M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
39.0%
FKWL

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
FKWL
FKWL
RNA
RNA
Revenue
$11.9M
$12.5M
Net Profit
$533.6K
$-174.4M
Gross Margin
17.1%
Operating Margin
0.4%
-1513.5%
Net Margin
4.5%
-1398.3%
Revenue YoY
-33.1%
434.0%
Net Profit YoY
133.3%
-117.0%
EPS (diluted)
$0.05
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FKWL
FKWL
RNA
RNA
Q4 25
$11.9M
Q3 25
$12.7M
$12.5M
Q2 25
$6.9M
$3.8M
Q1 25
$8.0M
$1.6M
Q4 24
$17.8M
$3.0M
Q3 24
$13.3M
$2.3M
Q2 24
$6.1M
$2.0M
Q1 24
$6.2M
$3.5M
Net Profit
FKWL
FKWL
RNA
RNA
Q4 25
$533.6K
Q3 25
$640.5K
$-174.4M
Q2 25
$-342.2K
$-157.3M
Q1 25
$-644.8K
$-115.8M
Q4 24
$228.7K
$-102.3M
Q3 24
$515.2K
$-80.4M
Q2 24
$-1.8M
$-70.8M
Q1 24
$-1.2M
$-68.9M
Gross Margin
FKWL
FKWL
RNA
RNA
Q4 25
17.1%
Q3 25
22.8%
Q2 25
18.0%
Q1 25
16.9%
Q4 24
18.2%
Q3 24
15.5%
Q2 24
10.5%
Q1 24
8.4%
Operating Margin
FKWL
FKWL
RNA
RNA
Q4 25
0.4%
Q3 25
4.6%
-1513.5%
Q2 25
-19.0%
-4448.7%
Q1 25
-24.6%
-8360.9%
Q4 24
4.5%
-4069.6%
Q3 24
-2.8%
-4200.9%
Q2 24
-36.7%
-4040.4%
Q1 24
-25.2%
-2178.6%
Net Margin
FKWL
FKWL
RNA
RNA
Q4 25
4.5%
Q3 25
5.0%
-1398.3%
Q2 25
-4.9%
-4089.3%
Q1 25
-8.1%
-7360.0%
Q4 24
1.3%
-3439.5%
Q3 24
3.9%
-3441.7%
Q2 24
-28.9%
-3461.8%
Q1 24
-19.0%
-1943.4%
EPS (diluted)
FKWL
FKWL
RNA
RNA
Q4 25
$0.05
Q3 25
$0.05
$-1.27
Q2 25
$-0.03
$-1.21
Q1 25
$-0.05
$-0.90
Q4 24
$0.02
$-0.80
Q3 24
$0.04
$-0.65
Q2 24
$-0.16
$-0.65
Q1 24
$-0.10
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FKWL
FKWL
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$24.3M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$35.1M
$1.9B
Total Assets
$53.0M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FKWL
FKWL
RNA
RNA
Q4 25
$24.3M
Q3 25
$25.3M
$350.2M
Q2 25
$25.9M
$243.9M
Q1 25
$25.3M
$254.2M
Q4 24
$21.9M
$219.9M
Q3 24
$40.7M
$370.2M
Q2 24
$37.5M
$575.8M
Q1 24
$31.7M
$471.4M
Stockholders' Equity
FKWL
FKWL
RNA
RNA
Q4 25
$35.1M
Q3 25
$35.1M
$1.9B
Q2 25
$34.5M
$1.2B
Q1 25
$35.3M
$1.3B
Q4 24
$36.0M
$1.4B
Q3 24
$35.8M
$1.5B
Q2 24
$35.1M
$1.2B
Q1 24
$36.9M
$830.9M
Total Assets
FKWL
FKWL
RNA
RNA
Q4 25
$53.0M
Q3 25
$53.3M
$2.1B
Q2 25
$51.3M
$1.4B
Q1 25
$49.7M
$1.5B
Q4 24
$54.5M
$1.6B
Q3 24
$51.6M
$1.6B
Q2 24
$46.7M
$1.3B
Q1 24
$50.0M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FKWL
FKWL
RNA
RNA
Operating Cash FlowLast quarter
$-4.1M
$-156.2M
Free Cash FlowOCF − Capex
$-4.1M
$-156.9M
FCF MarginFCF / Revenue
-34.3%
-1257.6%
Capex IntensityCapex / Revenue
0.1%
5.7%
Cash ConversionOCF / Net Profit
-7.66×
TTM Free Cash FlowTrailing 4 quarters
$-9.2M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FKWL
FKWL
RNA
RNA
Q4 25
$-4.1M
Q3 25
$-1.5M
$-156.2M
Q2 25
$2.3M
$-199.7M
Q1 25
$-5.9M
$-124.8M
Q4 24
$2.7M
$-99.9M
Q3 24
$2.7M
$-65.6M
Q2 24
$6.2M
$-65.0M
Q1 24
$-779.0K
$-70.4M
Free Cash Flow
FKWL
FKWL
RNA
RNA
Q4 25
$-4.1M
Q3 25
$-1.5M
$-156.9M
Q2 25
$2.3M
$-203.0M
Q1 25
$-5.9M
$-128.6M
Q4 24
$2.7M
$-103.8M
Q3 24
$2.6M
$-67.3M
Q2 24
$6.2M
$-65.5M
Q1 24
$-816.0K
$-71.3M
FCF Margin
FKWL
FKWL
RNA
RNA
Q4 25
-34.3%
Q3 25
-11.7%
-1257.6%
Q2 25
33.6%
-5277.1%
Q1 25
-73.7%
-8174.3%
Q4 24
15.4%
-3491.0%
Q3 24
19.9%
-2881.8%
Q2 24
101.3%
-3204.6%
Q1 24
-13.2%
-2012.3%
Capex Intensity
FKWL
FKWL
RNA
RNA
Q4 25
0.1%
Q3 25
0.0%
5.7%
Q2 25
0.1%
86.9%
Q1 25
0.0%
238.6%
Q4 24
0.0%
131.7%
Q3 24
0.2%
72.9%
Q2 24
0.0%
26.0%
Q1 24
0.6%
25.8%
Cash Conversion
FKWL
FKWL
RNA
RNA
Q4 25
-7.66×
Q3 25
-2.32×
Q2 25
Q1 25
Q4 24
11.99×
Q3 24
5.18×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons